NJBiz -- Among the hurdles that pharmaceutical companies face in bringing a new drug to market is getting Food and Drug Administration approval for the trade name of the product. Merck and Co. Inc. stumbled over that hurdle late last month when the FDA not only failed to approve the company’s highly anticipated new cholesterol drug, but turned thumbs down on the proposed name as well.
